Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics (CRSP -1.64%) isn't a stock that's wanting for reasons to invest. Between the solid launch of its first commercialized therapy and a promising pipeline that's continuing to deliver, this biotech is on track for growth.

1 big new Green Flag for CRISPR Therapeutics' Stock

Sarepta Therapeutics

Voyager Therapeutics

We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

Iovance Biotherapeutics

Investors looking for stocks that can make dramatic gains can find some in the biopharmaceutical industry. Right now, there are a pair of biopharma stocks that Wall Street expects to rocket higher in 2025.

2 Growth Stocks That Could Rocket Higher in 2025: Are They Right for Your Portfolio?

CRISPR Therapeutics (CRSP -3.57%) is recognized as a pioneer in the field of gene therapy. This biotechnology has the potential to revolutionize medicine through precise modifications of a person's DNA to treat and cure genetic diseases.

3 Things You Need to Know if You Buy CRISPR Therapeutics Today

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol-

CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting

CRISPR Therapeutics (CRSP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

CRISPR Therapeutics (CRSP) Upgraded to Buy: What Does It Mean for the Stock?

Exelixis

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500.

2 Biotech Stocks to Buy Hand Over Fist in December

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?

Why Is CRISPR Therapeutics (CRSP) Up 0.8% Since Last Earnings Report?

Celsius Holdings

KB Home

It's getting harder these days to find great growth stocks trading for less than $100 a share. It almost seems like a higher price is one of the criteria.

3 of the Best Growth Stocks You Can Buy for Less than $100

The average of price targets set by Wall Street analysts indicates a potential upside of 58.3% in CRISPR Therapeutics (CRSP). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Think CRISPR Therapeutics (CRSP) Could Surge 58.3%: Read This Before Placing a Bet

Ark Invest chief Cathie Wood is known for scooping up shares of innovators early in their growth stories and holding on for the long term. The idea is to get in on these players for a bargain price, and then benefit as they launch products and revenue gains momentum.

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More than 65%

On Nov. 21, shares of CRISPR Therapeutics (CRSP 3.44%) were down 47% from a peak they reached in March. This might be a little surprising to folks who have been following this developer of gene therapies.

Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip?

Summit Therapeutics

Viking Therapeutics

3 Monster Stocks in the Making

CRISPR Therapeutics AG (NASDAQ:CRSP ) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call Participants Maury Raycroft - Jefferies Maury Raycroft Hi, everyone. My name is Maury Raycroft, I'm one of the biotech analysts at Jeffreys.

CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)

The decline in CRSP's share price could be due to the beating the drug/biotech sector has been taking in the past couple of months, resulting from pipeline setbacks and guidance cuts.

CRISPR Therapeutics Stock Falls 7% in Two Weeks: Time to Hold or Sell?

2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More

CRISPR Therapeutics AG (NASDAQ:CRSP ) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Participants Debjit Chattopadhyay - Guggenheim Partners Debjit Chattopadhyay Good afternoon and thank you for joining us at Guggenheim's Inaugural Healthcare Innovations Conference. I am Debjit and one of the therapeutic analysts here.

CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)

Where Will CRISPR Therapeutics Be in 3 Years?

ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT.

CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference

Archer Aviation

IonQ

These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation.

3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029

CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost. Despite no Q3 revenue from Casgevy, CRISPR maintains a strong cash position and continues to advance its diverse pipeline, including CAR-T and in-vivo therapies. Vertex's partnership and investment highlight Casgevy's potential, but long-term success hinges on improving treatment processes and securing further drug approvals.

Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism

The mean of analysts' price targets for CRISPR Therapeutics (CRSP) points to a 62.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 62.75% Upside in CRISPR Therapeutics (CRSP): Can the Stock Really Move This High?

CRISPR Therapeutics reports mixed third-quarter results. The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well.

CRSP's Q3 Loss Narrower Than Expected, Sales Miss Estimates

CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.33. This compares to loss of $1.41 per share a year ago.

CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Lags Revenue Estimates

-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada-

News for CRISPR Therapeutics Stock (CRSP)